Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen Inc. (BIIB) furnished third-quarter results. The company submitted a press release announcing results of operations and financial condition for the quarter ended September 30, 2025, furnished as Exhibit 99.1.
The press release was provided under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. Biogen’s common stock trades on the Nasdaq Global Select Market under the symbol BIIB.
Biogen Inc. announced a preliminary estimate for the quarter ended September 30, 2025: it expects approximately $2 million of acquired in‑process research and development, upfront and milestone expense. The company estimates this will reduce GAAP and non‑GAAP net income per diluted share for Q3 2025 by about ($0.01) per share.
Biogen began presenting this expense as a separate line item starting in the first quarter of 2025 to reflect costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in‑process R&D. Results for the quarter have not been finalized and remain subject to financial statement closing procedures.
Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on 10/02/2025. He had restricted stock units (RSUs) vest that resulted in an acquisition of 502.6667 shares at no cash cost (code M), and on the same date he disposed of 8 shares by sale at $155.25 (code F), leaving him with 494.6667 shares reported as beneficially owned. The RSUs were granted on 10/02/2023 and vest in three equal annual installments beginning one year after the grant date; the filing was signed by an attorney-in-fact on 10/06/2025.
Priya Singhal, Head of Development at Biogen Inc. (BIIB), reported a series of equity transactions dated 08/29/2025 and 09/02/2025. A grant of 1,669 restricted stock units (RSUs) vested (recorded as an acquisition at $0) increasing her beneficial ownership before sales to 7,096.1428 shares. On 08/29/2025 she sold 807 shares at $132.22 and on 09/02/2025 she sold 517 shares at $133.55, leaving her with 5,772.1428 shares following the reported transactions. The filing notes the RSU award was granted on September 1, 2022 and vests in three equal annual installments.
Priya Singhal, Head of Development at Biogen Inc. (BIIB), reported a series of equity transactions dated 08/29/2025 and 09/02/2025. A grant of 1,669 restricted stock units (RSUs) vested (recorded as an acquisition at $0) increasing her beneficial ownership before sales to 7,096.1428 shares. On 08/29/2025 she sold 807 shares at $132.22 and on 09/02/2025 she sold 517 shares at $133.55, leaving her with 5,772.1428 shares following the reported transactions. The filing notes the RSU award was granted on September 1, 2022 and vests in three equal annual installments.
Biogen Inc. (BIIB) has filed a Form 144 notifying a proposed sale of 517 shares of common stock through Fidelity Brokerage Services. The filing lists an aggregate market value of $69,045.35 for the shares and states an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired on 09/01/2025 by restricted stock vesting from the issuer and payment is listed as compensation.
The filing shows 146,614,598 shares outstanding for the issuer. No securities sold in the past three months are reported and the filer represents there is no undisclosed material adverse information. The notice identifies Fidelity Brokerage Services LLC as the broker and includes the standard certification and signature/representation language required by Rule 144.
Biogen Inc. (BIIB) has filed a Form 144 notifying a proposed sale of 517 shares of common stock through Fidelity Brokerage Services. The filing lists an aggregate market value of $69,045.35 for the shares and states an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired on 09/01/2025 by restricted stock vesting from the issuer and payment is listed as compensation.
The filing shows 146,614,598 shares outstanding for the issuer. No securities sold in the past three months are reported and the filer represents there is no undisclosed material adverse information. The notice identifies Fidelity Brokerage Services LLC as the broker and includes the standard certification and signature/representation language required by Rule 144.
Biogen held its 2025 Annual Meeting of Stockholders on June 17, 2025, with three key matters put to vote. All eleven nominated directors were successfully elected to serve one-year terms until the 2026 annual meeting, with notable strong support for Lloyd Minor, Menelas Pangalos, and Monish Patolawala, each receiving over 114 million votes in favor.
Key voting outcomes include:
- Independent Auditor Appointment: PricewaterhouseCoopers LLP was ratified as the independent auditor for FY2025 with strong support (120,065,433 votes in favor)
- Say-on-Pay Vote: The executive compensation package was approved, though with more divided support - 78.5 million votes in favor versus 37.1 million against
The relatively split vote on executive compensation (67.8% approval) suggests some shareholder concerns about leadership remuneration. The high broker non-votes (10.2 million) across most items indicate significant holdings by institutional investors who did not provide voting instructions.